To improve the lives of patients affected by transthyretin amyloidoses through innovative therapeutic approaches.
Polyneuropathy and CNS Angiopathy
What is happening in our universe.
BSIM Therapeutics’ Research, Development and Innovation (RDI) system has been certified through the NP 4457:2007 standard.
BSIM has attended the 2nd European ATTR amyloidosis Meeting for Doctors and Patients
BSIM Therapeutics is awarded a United States Patent (Patent #10,377,729) for one of its promising technologies in the stabilization of transthyretin (TTR)
Results published in Amyloid, The Journal, show that one of the technologies developed by BSIM Therapeutics stabilizes transthyretin in the cerebrospinal fluid and in the vitreous humor.
By continuing to browse the site, you expressly agree that cookies will be stored on your computer to help measure statistics of visits and improve the quality of the contents offered.Learn more